Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Target Raised at Wells Fargo & Company

Iovance Biotherapeutics (NASDAQ:IOVA) had its price target increased by stock analysts at Wells Fargo & Company from $14.00 to $18.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 23.25% from the company’s current price.

IOVA has been the subject of a number of other reports. Robert W. Baird set a $6.00 price target on Iovance Biotherapeutics in a research note on Friday, August 7th. Citizens Jmp increased their target price on Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Citigroup reiterated an “outperform” rating on shares of Iovance Biotherapeutics in a research report on Friday, August 7th. TD Cowen boosted their price target on Iovance Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a report on Monday, August 24th. Finally, HC Wainwright upped their price target on Iovance Biotherapeutics from $9.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.40.

Iovance Biotherapeutics Trading Up 1.1%

NASDAQ IOVA traded up $0.15 during trading hours on Wednesday, reaching $14.60. 7,758,976 shares of the company traded hands, compared to its average volume of 15,775,896. The stock has a market capitalization of $6.62 billion, a PE ratio of -19.93 and a beta of 0.83. Iovance Biotherapeutics has a 12 month low of $1.76 and a 12 month high of $15.30. The company has a 50 day moving average of $7.79 and a two-hundred day moving average of $5.27.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. The company had revenue of $99.31 million during the quarter, compared to the consensus estimate of $87.83 million. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The company’s revenue was up 65.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.33) EPS. On average, equities research analysts anticipate that Iovance Biotherapeutics will post -0.49 earnings per share for the current year.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. KBC Group NV bought a new position in shares of Iovance Biotherapeutics during the first quarter valued at approximately $34,000. Sanctuary Advisors LLC bought a new position in shares of Iovance Biotherapeutics during the first quarter worth about $38,000. Fifth Third Bancorp bought a new position in shares of Iovance Biotherapeutics during the first quarter worth about $39,000. Ceera Investments LLC acquired a new stake in shares of Iovance Biotherapeutics in the 1st quarter worth about $44,000. Finally, First National Bank & Trust Co. of Newtown acquired a new stake in shares of Iovance Biotherapeutics in the 2nd quarter worth about $51,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Key Stories Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance raised 2026 revenue guidance to $410 million-$420 million, up from $350 million-$370 million previously and above analyst estimates near $402 million. Management cited strong U.S. demand for Amtagvi (lifileucel) and Proleukin, providing the primary catalyst for the stock’s advance. Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
• Positive Sentiment: The outlook increase suggests commercial traction for Iovance’s melanoma treatment portfolio and supports expectations for continued revenue growth. Reports highlighted strong melanoma-drug demand and an anticipated increase of roughly 60% in revenue. Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth
• Positive Sentiment: HC Wainwright raised its price target from $9 to $20 and maintained a Buy rating, implying additional upside based on the referenced $14.45 share price. The higher target reflects greater confidence in Iovance’s commercial turnaround.
• Positive Sentiment: The shares advanced more than 30% on unusually heavy volume and reached their highest level since 2024, indicating that the guidance update attracted substantial market participation. Iovance hits highest since 2024 as analysts cheer guidance raise
• Neutral Sentiment: Despite the stronger revenue outlook, Iovance remains unprofitable, and its valuation now reflects substantial expectations for continued execution.
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revisions may not support further near-term gains. Another analysis argued that much of the turnaround may already be priced in and downgraded the stock to Hold, creating a potential consolidation risk after the sharp rally. Iovance Biotherapeutics Surges: Is This an Indication of Further Gains?

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. Its platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded in a manufacturing facility and returned to the patient to help recognize and attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.